2. Key points of the resolution .................................................................................... 2 2.1 Additional benefit of the medicinal product in relation to the appropriate comparator therapy ................................................................................................................... 3 2.1.1 Approved therapeutic indication of Empagliflozin (Jardiance) in accordance with the product information ......................................................................................... 3 2.1.2 Appropriate comparator therapy ..................................................................... 3 2.1.3 Extent and probability of the additional benefit .............................................. 6 2.1.4 Summary of the assessment .......................................................................... 13 2.2 Number of patients or demarcation of patient groups eligible for treatment ......... 14 2.3 Requirements for a quality-assured application ..................................................... 14 2.4 Treatment costs .................................................................................................... 14
{"title":"Justification","authors":"Herner Saeverot","doi":"10.4324/9781003193463-2","DOIUrl":"https://doi.org/10.4324/9781003193463-2","url":null,"abstract":"2. Key points of the resolution .................................................................................... 2 2.1 Additional benefit of the medicinal product in relation to the appropriate comparator therapy ................................................................................................................... 3 2.1.1 Approved therapeutic indication of Empagliflozin (Jardiance) in accordance with the product information ......................................................................................... 3 2.1.2 Appropriate comparator therapy ..................................................................... 3 2.1.3 Extent and probability of the additional benefit .............................................. 6 2.1.4 Summary of the assessment .......................................................................... 13 2.2 Number of patients or demarcation of patient groups eligible for treatment ......... 14 2.3 Requirements for a quality-assured application ..................................................... 14 2.4 Treatment costs .................................................................................................... 14","PeriodicalId":113730,"journal":{"name":"Indirect Education","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126198932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：